These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15366325)

  • 1. Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.
    Huupponen R; Anttila M; Rouru J; Kanerva H; Miettinen T; Scheinin M
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):449-55. PubMed ID: 15366325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of deramciclane during multiple oral dosing.
    Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
    Huupponen R; Paija O; Salonen M; Björklund H; Rouru J; Anttila M
    Drugs R D; 2003; 4(6):339-45. PubMed ID: 14584962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers.
    Kanerva H; Kilkku O; Heinonen E; Helminen A; Rouru J; Tarpila S; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A
    Biopharm Drug Dispos; 1999 Oct; 20(7):327-34. PubMed ID: 10760840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing.
    Kanerva H; Huuskonen H; Alhonen-Raatesalmi A; Nevalainen T; Urtti A
    Biopharm Drug Dispos; 1998 Nov; 19(8):531-9. PubMed ID: 9840215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
    Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J
    Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat.
    Nemes KB; Abermann M; Bojti E; Grézal G; Al-Behaisi S; Klebovich I
    J Pharm Pharmacol; 2000 Jan; 52(1):47-51. PubMed ID: 10716602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of deramciclane in rabbits.
    Lengyel J; Bojti E; Bolehovszky A; Grézal G; Klebovich I; Magyar K
    Arzneimittelforschung; 1998 Nov; 48(11):1063-8. PubMed ID: 9850425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
    Drabant S; Nemes KB; Horváth V; Tolokán A; Grézal G; Anttila M; Gachályi B; Kanerva H; Al-Behaisi S; Horvai G; Klebovich I
    Eur J Pharm Biopharm; 2004 Nov; 58(3):689-95. PubMed ID: 15451546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different absorption profiles of deramciclane in man and in dog.
    Kanerva H; Klebovich I; Drabant S; Urtti A; Nevalainen T
    J Pharm Pharmacol; 1998 Oct; 50(10):1087-93. PubMed ID: 9821653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits.
    Lengyel J; Bolehovszky A; Klebovich I; Aberman M; Magyar K
    Arzneimittelforschung; 1998 May; 48(5):455-60. PubMed ID: 9638311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascending-Dose Study of Controlled-Release Ketamine Tablets in Healthy Volunteers: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability.
    Glue P; Medlicott NJ; Surman P; Lam F; Hung N; Hung CT
    J Clin Pharmacol; 2020 Jun; 60(6):751-757. PubMed ID: 32065415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.